Center for Interventional Paediatric Psychopharmacology

London, United Kingdom

Center for Interventional Paediatric Psychopharmacology

London, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Glennon J.,Radboud University Nijmegen | Purper-Ouakil D.,Medecine Psychologique de l'Enfant et de l'Adolescent | Purper-Ouakil D.,French Institute of Health and Medical Research | Bakker M.,Radboud University Nijmegen | And 23 more authors.
European Child and Adolescent Psychiatry | Year: 2014

In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology. © 2013, The Author(s).


Bolea-Alamanac B.,University of Bristol | Nutt D.J.,Imperial College London | Adamou M.,South West Yorkshire Trust | Asherson P.,Institute of Psychiatry | And 9 more authors.
Journal of Psychopharmacology | Year: 2014

Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment. © 2014 The Author(s).

Loading Center for Interventional Paediatric Psychopharmacology collaborators
Loading Center for Interventional Paediatric Psychopharmacology collaborators